Early Detection Research Network

Showe 29-gene signature for lung cancer

This biomarker is also known as:
  • Showe 29-gene signature for lung cancer,


A 29-gene peripheral blood gene expression signature that separates patients with non-small cell lung cancer (NSCLC) tumors and patient controls with 86% accuracy (91% sensitivity, 80% specificity). Subjects were primarily smokers and former smokers. The 29 genes, minus one that did not match a gene symbol in the naming database: RSF1, DYRK2, YY1, C19orf12, THEM2, TRIO, MYADM, BAIAP2, ROGDI, DNAJB14, BRE, TMEM41A, C9orf64, FAM110A, PCNXL2, REST, C19orf62, C13orf27, ASCC3, SLC1A5, PTPLAD1, MRE11A, GTPBP10, SERPINI2, CREB1, CCDC53, USP48, ZSCAN2


There are no datasets associated with this biomarker.

QA State: Curated
HGNC Name:

Panel Details

No member markers defined for this panel.

The following organs have data associated with this biomarker…


Phase: One
QA State: Curated


This gene expression signature found in peripheral blood mononuclear cells (PBMCs) can distinguish patients with early-stage NSCLC from appropriate at-risk controls with nonmalignant lung diseases common to both patient and control classes.

Performance Comment

The case and control groups were similar in terms of age, race, gender, and smoking history. Fifty-five percent of the cancer patients were stage 1, 13% were stage 2, and 32% were stages 3 and 4. Eighty-four percent of the control group and 93% of the NSCLC group were current or previous smokers. The initial clinical use of our biomarkers is more likely to provide additional data to a clinician trying to evaluate a pulmonary nodule diagnosed by CT scan or chest X-ray. Based on prevalence data from a large CT screening study, the 29-gene NSCLC classifier has a positive predictive value of 0.06 and a negative predictive value of 1.00. This is comparable with the positive predictive and negative predictive values calculated using the same prevalence values for the 80-gene classifier derived from lung epithelial cells obtained from bronchial brushing recently described by Spira and colleagues (see Spira 80-marker panel for lung cancer and Spira 80-marker panel plus clinical factors in this database).

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.

No other associated resources found.